• About the Society
  • SPIE Altruism
  • Diversity
  • International Day of Light
  • Fellows and Senior Members
  • Awards Programs
  • Press Room
  • Public Policy
  • Related Organizations
  • Jobs at SPIE
 
Print PageEmail Page

Maryellen Giger advises in development of machine-learning technology for cancer diagnosis

28 July 2017

Maryellen Giger

Maryellen Giger

Quantitative Insights, Inc. (QI) has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for its QuantXTM Advanced system, a computer-aided diagnosis (CADx) platform incorporating machine learning for the evaluation of breast abnormalities.

QuantXTM incorporates licensed technology from the research labs of SPIE President-Elect Maryellen Giger, who acts as scientific advisor for the company. Giger is also a professor and Vice-Chair of Radiology for Basic Science Research at the University of Chicago. Giger has been conducting research on computer-aided diagnosis and quantitative image analysis in breast cancer, lung cancer, and bone diseases for more than 25 years.

"QI has demonstrated that they can successfully take meaningful clinical innovations from research labs and clinics, develop them into products, take them through the regulatory process, and to the market," Giger said.

QI has a long-standing collaborative relationship with the University of Chicago and is supported by the university's Polsky Center for Entrepreneurship and Innovation.

In the FDA clinical study, QuantXTM was shown to improve the diagnostic performance of radiologists by enabling faster and more accurate diagnosis, more personalized treatments, and better outcomes for patients.

Read the full press release from Quantitative Insights, Inc.

Also see the SPIE press release: Maryellen Giger elected to SPIE presidential chain.